<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592240</url>
  </required_header>
  <id_info>
    <org_study_id>B1481015</org_study_id>
    <secondary_id>2012-001226-10</secondary_id>
    <nct_id>NCT01592240</nct_id>
  </id_info>
  <brief_title>Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin</brief_title>
  <official_title>A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose-ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Monthly And Twice Monthly Subcutaneous Dosing For Six Months In Hypercholesterolemic Subjects On A Statin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615
      administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with
      high cholesterol whose LDL-cholesterol is &gt;/=80 mg/dL on background treatment with a statin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Anti-drug (Anti-PF-04950615) Antibodies (ADA)</measure>
    <time_frame>Baseline up to Day 211 for every 28 days groups and Baseline up to Day 225 for every 14 days groups</time_frame>
    <description>Participants with titer value greater than or equal to 4.32 nanogram per milliliter were considered positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Injection Site Adverse Events</measure>
    <time_frame>Baseline up to Day 211 for 28 days groups and Baseline up to Day 225 for 14 days groups</time_frame>
    <description>Injection site adverse events included injection site bruising, discomfort, erythema, hemorrhage, induration, inflammation, pain, paresthesia, pruritus, swelling, urticaria, reaction and rash.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of PF-04950615 at Week 12 and 24</measure>
    <time_frame>Week 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Low Density Lipoprotein-cholesterol Less Than (&lt;) 100, &lt;70, &lt;40 and &lt;25 Milligram Per Deciliter (mg/dL)</measure>
    <time_frame>Week 12, 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">354</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Q28d Dosing Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Q14d Dosing Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBO</intervention_name>
    <description>Placebo Q28d</description>
    <arm_group_label>Q28d Dosing Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200mg PF-04950615 (RN316)</intervention_name>
    <description>PF-04950615 200 mg, Q28d</description>
    <arm_group_label>Q28d Dosing Arm</arm_group_label>
    <other_name>PF-04950615 (RN316)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300mg PF-04950615 (RN316)</intervention_name>
    <description>PF-04950615 300 mg, Q28d</description>
    <arm_group_label>Q28d Dosing Arm</arm_group_label>
    <other_name>PF-04950615 (RN316)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBO</intervention_name>
    <description>Placebo, Q14d</description>
    <arm_group_label>Q14d Dosing Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>PF-04950615 50mg, Q14d</description>
    <arm_group_label>Q14d Dosing Arm</arm_group_label>
    <other_name>PF-04950615 (RN316)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>PF-04950615 100 mg, Q14d</description>
    <arm_group_label>Q14d Dosing Arm</arm_group_label>
    <other_name>PF-04950615 (RN316)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>PF-04950615 150mg, Q14d</description>
    <arm_group_label>Q14d Dosing Arm</arm_group_label>
    <other_name>PF-04950615 (RN316)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects should be receiving a stable dose (at least 6 weeks) of any statin and
             continue on same dose of statin for the duration of this trial.

          -  Lipids should meet the following criteria on a background treatment with a statin at 2
             screening visits that occur at screening and at least 7 days prior to randomization on
             Day 1:

          -  Fasting LDL-C greater than or equal to 80 mg/dL (2.31 mmol/L);

          -  Fasting TG less than or equal to 400 mg/dL (4.52 mmol/L).

          -  Subject's fasting LDL-cholesterol must greater than or equal to 80 mg/dL (2.31 mmol/L
             at the initial screening visit, and the value at the second visit within 7 days of
             randomization must be not lower than 20% of this initial value to meet eligibility
             criterion for this trial.

        Exclusion Criteria:

          -  Participation in other studies within 3 months before the current study begins and/or
             during study participation.

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality
             that may increase the risk associated with study participation or investigational
             product administration or may interfere with the interpretation of study results and,
             in the judgment of the investigator, would make the subject inappropriate for entry
             into this study.

          -  Pregnant females; breastfeeding females; males and females of childbearing potential
             not using highly effective contraception or not agreeing to continue highly effective
             contraception for at least 63 days after last dose of investigational product.

          -  History of a cardiovascular or cerebrovascular event or procedure (eg, MI, stroke,
             TIA, angioplasty) during the past 6 months. Congestive heart failure (CHF), NYHA
             functional classes III or IV.

          -  Poorly controlled type 1 or type 2 diabetes mellitus (defined as HbA1c &gt;9%).

          -  Poorly controlled hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Affiliated Research Center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of James G. McMurray, MD</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Heart Group</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aureus Research Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universal Biopharma Research Institute Inc. - Alta Family Health Clinic</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Lucita M. Cruz, MD, Inc.</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Medical Associates</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zasa Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Health Center</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Network, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>In Vivo Clinical Research, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Care Family Rehab and Research Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Foundation, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall South Medical Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DMI Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Johns Center for Clinical Research</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Bridget Bellingar, DO</name>
      <address>
        <city>Seminole</city>
        <state>Florida</state>
        <zip>33774</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Clinical Research</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Valley Clinical Research Center, LLC</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Heart &amp; Vascular Specialists</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent City Clinical Research Center</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dybedal Clinical Research Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research, Inc.</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Clinical Research and Osteoporosis Center, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central New York Clinical Research</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, Inc.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Internal Medicine Consultants</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ardmore Family Practice</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentral Clinical Research Services</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, LTD.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert J. Weisbrot, M.D., Inc.</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Research</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Center for Cardiovascular Disease Prevention</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protenium Clinical Research, LLC</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paragon Research Center, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research- Norfolk, Inc</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481015&amp;StudyName=Monthly%20And%20Twice%20Monthly%20Subcutaneous%20Dosing%20Of%20PF-04950615%20%28RN316%29%20%20In%20Hypercholesterolemic%20Subjects%20On%20A%20Statin</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <results_first_submitted>October 27, 2017</results_first_submitted>
  <results_first_submitted_qc>October 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2017</results_first_posted>
  <disposition_first_submitted>October 14, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>October 14, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 23, 2014</disposition_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-04950615</keyword>
  <keyword>RN316</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo: Every 14 Days</title>
          <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>PF-04950615 50 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>PF-04950615 100 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>PF-04950615 150 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo: Every 28 Days</title>
          <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
        </group>
        <group group_id="P6">
          <title>PF-04950615 200 mg: Every 28 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
        </group>
        <group group_id="P7">
          <title>PF-04950615 300 mg: Every 28 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="47"/>
                <participants group_id="P7" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Entrance Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo: Every 14 Days</title>
          <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>PF-04950615 50 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>PF-04950615 100 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>PF-04950615 150 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Placebo: Every 28 Days</title>
          <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>PF-04950615 200 mg: Every 28 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
        </group>
        <group group_id="B7">
          <title>PF-04950615 300 mg: Every 28 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="51"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="51"/>
            <count group_id="B8" value="354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="9.84"/>
                    <measurement group_id="B2" value="59.1" spread="11.26"/>
                    <measurement group_id="B3" value="61.9" spread="9.58"/>
                    <measurement group_id="B4" value="61.4" spread="9.75"/>
                    <measurement group_id="B5" value="58.4" spread="11.62"/>
                    <measurement group_id="B6" value="60.3" spread="9.64"/>
                    <measurement group_id="B7" value="60.2" spread="8.17"/>
                    <measurement group_id="B8" value="60.3" spread="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized. Here &quot;Overall Number of Participants Analyzed&quot;, signifies number of participants those who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <population>Full analysis set included all participants who were randomized. Here &quot;Overall Number of Participants Analyzed&quot;, signifies number of participants those who were evaluable for this outcome measure.</population>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-10.14" upper_limit="4.98"/>
                    <measurement group_id="O2" value="-36.9" lower_limit="-44.55" upper_limit="-29.17"/>
                    <measurement group_id="O3" value="-47.6" lower_limit="-55.45" upper_limit="-39.85"/>
                    <measurement group_id="O4" value="-56.0" lower_limit="-63.60" upper_limit="-48.40"/>
                    <measurement group_id="O5" value="4.6" lower_limit="-4.59" upper_limit="13.73"/>
                    <measurement group_id="O6" value="-23.0" lower_limit="-32.00" upper_limit="-14.02"/>
                    <measurement group_id="O7" value="-40.3" lower_limit="-49.09" upper_limit="-31.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-34.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.06</ci_lower_limit>
            <ci_upper_limit>-23.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-45.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.93</ci_lower_limit>
            <ci_upper_limit>-34.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-53.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.14</ci_lower_limit>
            <ci_upper_limit>-42.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-27.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.49</ci_lower_limit>
            <ci_upper_limit>-14.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-44.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.65</ci_lower_limit>
            <ci_upper_limit>-32.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here &quot;Overall Number of Participants Analyzed&quot;, signifies number of participants those who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24</title>
          <population>Full analysis set included all participants who were randomized. Here &quot;Overall Number of Participants Analyzed&quot;, signifies number of participants those who were evaluable for this outcome measure.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-11.16" upper_limit="3.88"/>
                    <measurement group_id="O2" value="-32.0" lower_limit="-39.72" upper_limit="-24.37"/>
                    <measurement group_id="O3" value="-46.8" lower_limit="-54.44" upper_limit="-39.25"/>
                    <measurement group_id="O4" value="-44.7" lower_limit="-52.19" upper_limit="-37.16"/>
                    <measurement group_id="O5" value="-0.6" lower_limit="-7.69" upper_limit="6.54"/>
                    <measurement group_id="O6" value="-24.3" lower_limit="-31.21" upper_limit="-17.49"/>
                    <measurement group_id="O7" value="-30.9" lower_limit="-37.71" upper_limit="-24.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-28.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.15</ci_lower_limit>
            <ci_upper_limit>-17.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-43.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.90</ci_lower_limit>
            <ci_upper_limit>-32.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-41.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.66</ci_lower_limit>
            <ci_upper_limit>-30.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-23.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.70</ci_lower_limit>
            <ci_upper_limit>-13.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-30.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.24</ci_lower_limit>
            <ci_upper_limit>-20.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-6.34" upper_limit="7.54"/>
                    <measurement group_id="O2" value="-34.4" lower_limit="-41.47" upper_limit="-27.34"/>
                    <measurement group_id="O3" value="-41.7" lower_limit="-48.90" upper_limit="-34.54"/>
                    <measurement group_id="O4" value="-52.5" lower_limit="-59.51" upper_limit="-45.54"/>
                    <measurement group_id="O5" value="6.7" lower_limit="-1.30" upper_limit="14.73"/>
                    <measurement group_id="O6" value="-20.2" lower_limit="-28.10" upper_limit="-12.39"/>
                    <measurement group_id="O7" value="-34.4" lower_limit="-42.11" upper_limit="-26.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-7.39" upper_limit="5.64"/>
                    <measurement group_id="O2" value="-30.0" lower_limit="-36.64" upper_limit="-23.29"/>
                    <measurement group_id="O3" value="-41.0" lower_limit="-47.62" upper_limit="-34.42"/>
                    <measurement group_id="O4" value="-40.0" lower_limit="-46.55" upper_limit="-33.51"/>
                    <measurement group_id="O5" value="2.4" lower_limit="-4.08" upper_limit="8.96"/>
                    <measurement group_id="O6" value="-21.3" lower_limit="-27.63" upper_limit="-15.07"/>
                    <measurement group_id="O7" value="-26.6" lower_limit="-32.84" upper_limit="-20.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-35.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.91</ci_lower_limit>
            <ci_upper_limit>-25.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-42.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.30</ci_lower_limit>
            <ci_upper_limit>-32.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-53.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.97</ci_lower_limit>
            <ci_upper_limit>-43.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-26.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.25</ci_lower_limit>
            <ci_upper_limit>-15.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-41.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.32</ci_lower_limit>
            <ci_upper_limit>-29.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-29.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.42</ci_lower_limit>
            <ci_upper_limit>-19.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-40.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.43</ci_lower_limit>
            <ci_upper_limit>-30.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-39.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.37</ci_lower_limit>
            <ci_upper_limit>-29.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-23.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.88</ci_lower_limit>
            <ci_upper_limit>-14.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-29.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.13</ci_lower_limit>
            <ci_upper_limit>-20.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-1.80" upper_limit="2.39"/>
                    <measurement group_id="O2" value="1.9" lower_limit="-0.20" upper_limit="4.06"/>
                    <measurement group_id="O3" value="2.0" lower_limit="-0.08" upper_limit="4.13"/>
                    <measurement group_id="O4" value="0.8" lower_limit="-1.28" upper_limit="2.92"/>
                    <measurement group_id="O5" value="-1.0" lower_limit="-3.33" upper_limit="1.27"/>
                    <measurement group_id="O6" value="3.4" lower_limit="1.12" upper_limit="5.72"/>
                    <measurement group_id="O7" value="2.8" lower_limit="0.58" upper_limit="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-2.09" upper_limit="1.79"/>
                    <measurement group_id="O2" value="1.6" lower_limit="-0.44" upper_limit="3.57"/>
                    <measurement group_id="O3" value="0.6" lower_limit="-1.32" upper_limit="2.61"/>
                    <measurement group_id="O4" value="0.3" lower_limit="-1.60" upper_limit="2.28"/>
                    <measurement group_id="O5" value="0.2" lower_limit="-2.39" upper_limit="2.72"/>
                    <measurement group_id="O6" value="2.2" lower_limit="-0.32" upper_limit="4.66"/>
                    <measurement group_id="O7" value="0.2" lower_limit="-2.28" upper_limit="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>4.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.251</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>4.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.724</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.43</ci_lower_limit>
            <ci_upper_limit>3.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>4.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>7.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>3.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>7.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.225</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>4.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.571</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.725</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.268</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>5.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.996</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.55</ci_lower_limit>
            <ci_upper_limit>3.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-2.87" upper_limit="5.25"/>
                    <measurement group_id="O2" value="4.6" lower_limit="0.48" upper_limit="8.74"/>
                    <measurement group_id="O3" value="3.8" lower_limit="-0.27" upper_limit="7.89"/>
                    <measurement group_id="O4" value="2.5" lower_limit="-1.52" upper_limit="6.61"/>
                    <measurement group_id="O5" value="-0.4" lower_limit="-4.91" upper_limit="4.06"/>
                    <measurement group_id="O6" value="7.2" lower_limit="2.76" upper_limit="11.72"/>
                    <measurement group_id="O7" value="6.1" lower_limit="1.71" upper_limit="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-4.07" upper_limit="3.55"/>
                    <measurement group_id="O2" value="3.6" lower_limit="-0.27" upper_limit="7.55"/>
                    <measurement group_id="O3" value="0.6" lower_limit="-3.26" upper_limit="4.43"/>
                    <measurement group_id="O4" value="2.3" lower_limit="-1.49" upper_limit="6.11"/>
                    <measurement group_id="O5" value="1.7" lower_limit="-2.79" upper_limit="6.14"/>
                    <measurement group_id="O6" value="4.7" lower_limit="0.34" upper_limit="8.99"/>
                    <measurement group_id="O7" value="1.0" lower_limit="-3.27" upper_limit="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.246</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>3.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.38</ci_lower_limit>
            <ci_upper_limit>9.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.14</ci_lower_limit>
            <ci_upper_limit>8.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.643</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.40</ci_lower_limit>
            <ci_upper_limit>7.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>7.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>13.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>6.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>12.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.160</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>3.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>9.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.758</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.56</ci_lower_limit>
            <ci_upper_limit>6.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.347</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>2.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.81</ci_lower_limit>
            <ci_upper_limit>7.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.343</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>2.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.22</ci_lower_limit>
            <ci_upper_limit>9.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.824</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.87</ci_lower_limit>
            <ci_upper_limit>5.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-7.65" upper_limit="2.02"/>
                    <measurement group_id="O2" value="-21.4" lower_limit="-26.26" upper_limit="-16.48"/>
                    <measurement group_id="O3" value="-30.5" lower_limit="-35.40" upper_limit="-25.57"/>
                    <measurement group_id="O4" value="-34.9" lower_limit="-39.77" upper_limit="-30.04"/>
                    <measurement group_id="O5" value="2.3" lower_limit="-3.59" upper_limit="8.24"/>
                    <measurement group_id="O6" value="-12.2" lower_limit="-18.08" upper_limit="-6.40"/>
                    <measurement group_id="O7" value="-26.2" lower_limit="-31.92" upper_limit="-20.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-7.68" upper_limit="2.66"/>
                    <measurement group_id="O2" value="-22.2" lower_limit="-27.46" upper_limit="-16.89"/>
                    <measurement group_id="O3" value="-30.7" lower_limit="-35.92" upper_limit="-25.44"/>
                    <measurement group_id="O4" value="-27.9" lower_limit="-33.09" upper_limit="-22.75"/>
                    <measurement group_id="O5" value="-2.9" lower_limit="-7.70" upper_limit="1.83"/>
                    <measurement group_id="O6" value="-15.7" lower_limit="-20.26" upper_limit="-11.06"/>
                    <measurement group_id="O7" value="-19.8" lower_limit="-24.32" upper_limit="-15.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-18.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.44</ci_lower_limit>
            <ci_upper_limit>-11.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-27.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.55</ci_lower_limit>
            <ci_upper_limit>-20.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-32.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.95</ci_lower_limit>
            <ci_upper_limit>-25.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-14.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.89</ci_lower_limit>
            <ci_upper_limit>-6.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-28.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.83</ci_lower_limit>
            <ci_upper_limit>-20.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-19.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.07</ci_lower_limit>
            <ci_upper_limit>-12.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-28.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.52</ci_lower_limit>
            <ci_upper_limit>-20.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-25.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.73</ci_lower_limit>
            <ci_upper_limit>-18.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-12.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.35</ci_lower_limit>
            <ci_upper_limit>-6.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-16.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.47</ci_lower_limit>
            <ci_upper_limit>-10.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-7.31" upper_limit="3.45"/>
                    <measurement group_id="O2" value="-23.5" lower_limit="-28.94" upper_limit="-18.07"/>
                    <measurement group_id="O3" value="-32.5" lower_limit="-37.93" upper_limit="-27.01"/>
                    <measurement group_id="O4" value="-37.9" lower_limit="-43.29" upper_limit="-32.47"/>
                    <measurement group_id="O5" value="3.7" lower_limit="-2.55" upper_limit="9.86"/>
                    <measurement group_id="O6" value="-13.5" lower_limit="-19.60" upper_limit="-7.37"/>
                    <measurement group_id="O7" value="-27.1" lower_limit="-33.09" upper_limit="-21.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-7.27" upper_limit="4.25"/>
                    <measurement group_id="O2" value="-23.6" lower_limit="-29.48" upper_limit="-17.72"/>
                    <measurement group_id="O3" value="-32.5" lower_limit="-38.29" upper_limit="-26.64"/>
                    <measurement group_id="O4" value="-28.7" lower_limit="-34.50" upper_limit="-22.99"/>
                    <measurement group_id="O5" value="-1.4" lower_limit="-6.88" upper_limit="3.98"/>
                    <measurement group_id="O6" value="-16.8" lower_limit="-22.04" upper_limit="-11.54"/>
                    <measurement group_id="O7" value="-20.6" lower_limit="-25.76" upper_limit="-15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-21.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.23</ci_lower_limit>
            <ci_upper_limit>-13.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-30.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.19</ci_lower_limit>
            <ci_upper_limit>-22.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-35.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.59</ci_lower_limit>
            <ci_upper_limit>-28.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-17.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.87</ci_lower_limit>
            <ci_upper_limit>-8.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-30.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.45</ci_lower_limit>
            <ci_upper_limit>-21.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-22.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.32</ci_lower_limit>
            <ci_upper_limit>-13.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-30.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.13</ci_lower_limit>
            <ci_upper_limit>-22.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-27.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.38</ci_lower_limit>
            <ci_upper_limit>-19.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-15.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.90</ci_lower_limit>
            <ci_upper_limit>-7.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-19.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.70</ci_lower_limit>
            <ci_upper_limit>-11.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="-3.56" upper_limit="7.85"/>
                    <measurement group_id="O2" value="3.9" lower_limit="-1.83" upper_limit="9.67"/>
                    <measurement group_id="O3" value="7.6" lower_limit="1.84" upper_limit="13.33"/>
                    <measurement group_id="O4" value="6.0" lower_limit="0.25" upper_limit="11.68"/>
                    <measurement group_id="O5" value="2.2" lower_limit="-2.37" upper_limit="6.84"/>
                    <measurement group_id="O6" value="7.8" lower_limit="3.24" upper_limit="12.43"/>
                    <measurement group_id="O7" value="6.6" lower_limit="2.09" upper_limit="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-4.59" upper_limit="6.12"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-4.14" upper_limit="6.86"/>
                    <measurement group_id="O3" value="1.2" lower_limit="-4.19" upper_limit="6.58"/>
                    <measurement group_id="O4" value="4.9" lower_limit="-0.45" upper_limit="10.23"/>
                    <measurement group_id="O5" value="2.0" lower_limit="-3.76" upper_limit="7.72"/>
                    <measurement group_id="O6" value="0.6" lower_limit="-5.01" upper_limit="6.15"/>
                    <measurement group_id="O7" value="-0.2" lower_limit="-5.68" upper_limit="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.667</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.33</ci_lower_limit>
            <ci_upper_limit>9.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.187</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>5.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>13.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.352</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>3.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.25</ci_lower_limit>
            <ci_upper_limit>11.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>5.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>12.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.184</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>4.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.10</ci_lower_limit>
            <ci_upper_limit>10.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.879</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.09</ci_lower_limit>
            <ci_upper_limit>8.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.911</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.17</ci_lower_limit>
            <ci_upper_limit>8.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.283</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>4.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.44</ci_lower_limit>
            <ci_upper_limit>11.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.728</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.41</ci_lower_limit>
            <ci_upper_limit>6.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.587</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.13</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="-4.06" upper_limit="9.28"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-4.65" upper_limit="8.55"/>
                    <measurement group_id="O3" value="4.9" lower_limit="-1.63" upper_limit="11.48"/>
                    <measurement group_id="O4" value="9.1" lower_limit="2.52" upper_limit="15.77"/>
                    <measurement group_id="O5" value="2.2" lower_limit="-0.84" upper_limit="5.24"/>
                    <measurement group_id="O6" value="5.7" lower_limit="2.67" upper_limit="8.74"/>
                    <measurement group_id="O7" value="4.9" lower_limit="1.90" upper_limit="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-3.65" upper_limit="6.44"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-4.53" upper_limit="5.59"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-4.73" upper_limit="5.22"/>
                    <measurement group_id="O4" value="7.2" lower_limit="2.20" upper_limit="12.22"/>
                    <measurement group_id="O5" value="1.9" lower_limit="-1.86" upper_limit="5.56"/>
                    <measurement group_id="O6" value="1.0" lower_limit="-2.58" upper_limit="4.62"/>
                    <measurement group_id="O7" value="0.3" lower_limit="-3.23" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.890</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.05</ci_lower_limit>
            <ci_upper_limit>8.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.625</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>2.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.04</ci_lower_limit>
            <ci_upper_limit>11.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>6.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.86</ci_lower_limit>
            <ci_upper_limit>15.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>3.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>7.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.60</ci_lower_limit>
            <ci_upper_limit>6.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.812</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.01</ci_lower_limit>
            <ci_upper_limit>6.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.749</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.24</ci_lower_limit>
            <ci_upper_limit>5.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>5.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>12.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.752</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.99</ci_lower_limit>
            <ci_upper_limit>4.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.550</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.68</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-0.99" upper_limit="2.95"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-0.84" upper_limit="3.18"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.29" upper_limit="4.32"/>
                    <measurement group_id="O4" value="0.3" lower_limit="-1.65" upper_limit="2.33"/>
                    <measurement group_id="O5" value="1.7" lower_limit="-0.20" upper_limit="3.65"/>
                    <measurement group_id="O6" value="1.2" lower_limit="-0.67" upper_limit="3.13"/>
                    <measurement group_id="O7" value="2.1" lower_limit="0.25" upper_limit="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-2.54" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-0.94" upper_limit="2.72"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-1.66" upper_limit="1.91"/>
                    <measurement group_id="O4" value="0.3" lower_limit="-1.53" upper_limit="2.05"/>
                    <measurement group_id="O5" value="-0.1" lower_limit="-1.50" upper_limit="1.35"/>
                    <measurement group_id="O6" value="-0.8" lower_limit="-2.14" upper_limit="0.60"/>
                    <measurement group_id="O7" value="-0.5" lower_limit="-1.82" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.893</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.62</ci_lower_limit>
            <ci_upper_limit>3.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.355</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>4.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.655</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.45</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.719</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.20</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.768</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.31</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>4.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.483</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.62</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.420</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.67</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.694</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.36</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="-14.72" upper_limit="30.96"/>
                    <measurement group_id="O2" value="18.4" lower_limit="-4.09" upper_limit="40.90"/>
                    <measurement group_id="O3" value="8.5" lower_limit="-13.70" upper_limit="30.72"/>
                    <measurement group_id="O4" value="8.7" lower_limit="-14.06" upper_limit="31.38"/>
                    <measurement group_id="O5" value="5.4" lower_limit="0.61" upper_limit="10.12"/>
                    <measurement group_id="O6" value="3.8" lower_limit="-0.91" upper_limit="8.48"/>
                    <measurement group_id="O7" value="6.4" lower_limit="1.82" upper_limit="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="-15.36" upper_limit="26.30"/>
                    <measurement group_id="O2" value="15.3" lower_limit="-5.26" upper_limit="35.81"/>
                    <measurement group_id="O3" value="2.8" lower_limit="-17.47" upper_limit="23.03"/>
                    <measurement group_id="O4" value="8.5" lower_limit="-12.22" upper_limit="29.23"/>
                    <measurement group_id="O5" value="0.6" lower_limit="-2.72" upper_limit="3.89"/>
                    <measurement group_id="O6" value="-1.4" lower_limit="-4.59" upper_limit="1.78"/>
                    <measurement group_id="O7" value="-0.7" lower_limit="-3.89" upper_limit="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.527</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>10.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.73</ci_lower_limit>
            <ci_upper_limit>42.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.981</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.49</ci_lower_limit>
            <ci_upper_limit>32.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.974</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.72</ci_lower_limit>
            <ci_upper_limit>32.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.640</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.25</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.750</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.61</ci_lower_limit>
            <ci_upper_limit>7.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.509</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>9.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.41</ci_lower_limit>
            <ci_upper_limit>39.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.855</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.76</ci_lower_limit>
            <ci_upper_limit>26.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.839</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>3.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.39</ci_lower_limit>
            <ci_upper_limit>32.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.392</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.57</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.565</p_value>
            <method>Mixed models repeated measures analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.91</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="29.58"/>
                    <measurement group_id="O2" value="-35.8" spread="24.73"/>
                    <measurement group_id="O3" value="-52.7" spread="32.67"/>
                    <measurement group_id="O4" value="-58.6" spread="32.90"/>
                    <measurement group_id="O5" value="-0.4" spread="40.00"/>
                    <measurement group_id="O6" value="-19.5" spread="27.39"/>
                    <measurement group_id="O7" value="-37.6" spread="43.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="28.04"/>
                    <measurement group_id="O2" value="-31.7" spread="32.53"/>
                    <measurement group_id="O3" value="-55.0" spread="38.67"/>
                    <measurement group_id="O4" value="-46.9" spread="33.83"/>
                    <measurement group_id="O5" value="-6.4" spread="33.98"/>
                    <measurement group_id="O6" value="-24.5" spread="25.86"/>
                    <measurement group_id="O7" value="-28.6" spread="33.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="14.406"/>
                    <measurement group_id="O2" value="-18.96" spread="12.299"/>
                    <measurement group_id="O3" value="-26.45" spread="14.943"/>
                    <measurement group_id="O4" value="-31.64" spread="18.012"/>
                    <measurement group_id="O5" value="1.24" spread="16.624"/>
                    <measurement group_id="O6" value="-10.51" spread="15.318"/>
                    <measurement group_id="O7" value="-19.44" spread="22.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="13.481"/>
                    <measurement group_id="O2" value="-16.70" spread="15.860"/>
                    <measurement group_id="O3" value="-27.77" spread="16.993"/>
                    <measurement group_id="O4" value="-24.31" spread="16.491"/>
                    <measurement group_id="O5" value="-1.35" spread="14.426"/>
                    <measurement group_id="O6" value="-12.38" spread="13.365"/>
                    <measurement group_id="O7" value="-14.61" spread="17.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.654" spread="9.8020"/>
                    <measurement group_id="O2" value="-0.515" spread="17.6889"/>
                    <measurement group_id="O3" value="-2.956" spread="9.9368"/>
                    <measurement group_id="O4" value="-4.334" spread="14.3377"/>
                    <measurement group_id="O5" value="1.547" spread="12.0489"/>
                    <measurement group_id="O6" value="0.502" spread="15.1527"/>
                    <measurement group_id="O7" value="-5.195" spread="12.9577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.065" spread="13.2025"/>
                    <measurement group_id="O2" value="-1.893" spread="18.8951"/>
                    <measurement group_id="O3" value="-3.945" spread="16.2841"/>
                    <measurement group_id="O4" value="-3.205" spread="11.6380"/>
                    <measurement group_id="O5" value="2.718" spread="12.9153"/>
                    <measurement group_id="O6" value="2.191" spread="26.1574"/>
                    <measurement group_id="O7" value="-3.281" spread="16.9586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" spread="30.573"/>
                    <measurement group_id="O2" value="40.43" spread="333.949"/>
                    <measurement group_id="O3" value="-11.89" spread="22.517"/>
                    <measurement group_id="O4" value="-9.01" spread="35.644"/>
                    <measurement group_id="O5" value="9.28" spread="33.809"/>
                    <measurement group_id="O6" value="-0.91" spread="26.271"/>
                    <measurement group_id="O7" value="-11.93" spread="23.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" spread="43.596"/>
                    <measurement group_id="O2" value="43.97" spread="330.964"/>
                    <measurement group_id="O3" value="-10.18" spread="26.612"/>
                    <measurement group_id="O4" value="0.03" spread="50.256"/>
                    <measurement group_id="O5" value="10.18" spread="32.604"/>
                    <measurement group_id="O6" value="-0.79" spread="25.066"/>
                    <measurement group_id="O7" value="-5.42" spread="22.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="50.98"/>
                    <measurement group_id="O2" value="-11.8" spread="35.82"/>
                    <measurement group_id="O3" value="-6.0" spread="46.43"/>
                    <measurement group_id="O4" value="-20.3" spread="43.27"/>
                    <measurement group_id="O5" value="2.5" spread="39.66"/>
                    <measurement group_id="O6" value="-5.8" spread="38.21"/>
                    <measurement group_id="O7" value="-12.1" spread="51.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="46.55"/>
                    <measurement group_id="O2" value="-11.5" spread="49.20"/>
                    <measurement group_id="O3" value="-12.4" spread="38.58"/>
                    <measurement group_id="O4" value="-24.3" spread="57.43"/>
                    <measurement group_id="O5" value="-12.1" spread="40.35"/>
                    <measurement group_id="O6" value="-15.3" spread="47.53"/>
                    <measurement group_id="O7" value="2.8" spread="41.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.62" spread="71.415"/>
                    <measurement group_id="O2" value="2.81" spread="54.888"/>
                    <measurement group_id="O3" value="-3.77" spread="54.845"/>
                    <measurement group_id="O4" value="-15.61" spread="36.099"/>
                    <measurement group_id="O5" value="17.58" spread="54.707"/>
                    <measurement group_id="O6" value="17.32" spread="94.238"/>
                    <measurement group_id="O7" value="2.16" spread="80.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.26" spread="101.188"/>
                    <measurement group_id="O2" value="5.34" spread="59.092"/>
                    <measurement group_id="O3" value="-9.78" spread="39.626"/>
                    <measurement group_id="O4" value="-13.28" spread="44.197"/>
                    <measurement group_id="O5" value="-3.60" spread="40.646"/>
                    <measurement group_id="O6" value="15.72" spread="142.996"/>
                    <measurement group_id="O7" value="33.89" spread="131.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="54.92"/>
                    <measurement group_id="O2" value="-28.7" spread="76.49"/>
                    <measurement group_id="O3" value="-17.5" spread="87.65"/>
                    <measurement group_id="O4" value="-17.6" spread="74.45"/>
                    <measurement group_id="O5" value="9.0" spread="66.03"/>
                    <measurement group_id="O6" value="-9.1" spread="46.91"/>
                    <measurement group_id="O7" value="-15.7" spread="58.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="51.01"/>
                    <measurement group_id="O2" value="-13.0" spread="100.36"/>
                    <measurement group_id="O3" value="-25.2" spread="83.78"/>
                    <measurement group_id="O4" value="-25.5" spread="66.92"/>
                    <measurement group_id="O5" value="-12.0" spread="45.73"/>
                    <measurement group_id="O6" value="-20.7" spread="54.93"/>
                    <measurement group_id="O7" value="6.0" spread="50.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="42.789"/>
                    <measurement group_id="O2" value="-5.01" spread="40.253"/>
                    <measurement group_id="O3" value="-7.13" spread="35.229"/>
                    <measurement group_id="O4" value="-8.93" spread="50.315"/>
                    <measurement group_id="O5" value="13.92" spread="49.563"/>
                    <measurement group_id="O6" value="-1.88" spread="28.283"/>
                    <measurement group_id="O7" value="-5.91" spread="39.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="52.717"/>
                    <measurement group_id="O2" value="6.49" spread="51.960"/>
                    <measurement group_id="O3" value="-10.29" spread="32.708"/>
                    <measurement group_id="O4" value="-10.34" spread="32.992"/>
                    <measurement group_id="O5" value="-2.01" spread="29.868"/>
                    <measurement group_id="O6" value="-7.29" spread="35.954"/>
                    <measurement group_id="O7" value="13.90" spread="45.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="26.92"/>
                    <measurement group_id="O2" value="-37.5" spread="22.40"/>
                    <measurement group_id="O3" value="-55.0" spread="32.75"/>
                    <measurement group_id="O4" value="-59.6" spread="33.23"/>
                    <measurement group_id="O5" value="0.6" spread="38.04"/>
                    <measurement group_id="O6" value="-22.9" spread="29.05"/>
                    <measurement group_id="O7" value="-40.7" spread="44.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="26.84"/>
                    <measurement group_id="O2" value="-33.2" spread="29.21"/>
                    <measurement group_id="O3" value="-55.9" spread="38.79"/>
                    <measurement group_id="O4" value="-47.3" spread="33.71"/>
                    <measurement group_id="O5" value="-6.8" spread="31.49"/>
                    <measurement group_id="O6" value="-26.3" spread="22.98"/>
                    <measurement group_id="O7" value="-28.9" spread="34.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24</title>
        <time_frame>Baseline, Week 12, 24</time_frame>
        <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24</title>
          <population>Full analysis set included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="20.234"/>
                    <measurement group_id="O2" value="-28.34" spread="15.836"/>
                    <measurement group_id="O3" value="-38.52" spread="21.362"/>
                    <measurement group_id="O4" value="-44.86" spread="24.258"/>
                    <measurement group_id="O5" value="2.76" spread="20.337"/>
                    <measurement group_id="O6" value="-17.30" spread="22.324"/>
                    <measurement group_id="O7" value="-28.68" spread="30.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="18.694"/>
                    <measurement group_id="O2" value="-24.89" spread="18.938"/>
                    <measurement group_id="O3" value="-38.02" spread="23.039"/>
                    <measurement group_id="O4" value="-34.02" spread="22.788"/>
                    <measurement group_id="O5" value="-1.78" spread="17.145"/>
                    <measurement group_id="O6" value="-19.39" spread="17.304"/>
                    <measurement group_id="O7" value="-19.99" spread="24.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Anti-drug (Anti-PF-04950615) Antibodies (ADA)</title>
        <description>Participants with titer value greater than or equal to 4.32 nanogram per milliliter were considered positive.</description>
        <time_frame>Baseline up to Day 211 for every 28 days groups and Baseline up to Day 225 for every 14 days groups</time_frame>
        <population>Analysis set included all participants who received at least 1 dose of PF-04950615.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Anti-drug (Anti-PF-04950615) Antibodies (ADA)</title>
          <description>Participants with titer value greater than or equal to 4.32 nanogram per milliliter were considered positive.</description>
          <population>Analysis set included all participants who received at least 1 dose of PF-04950615.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="10.2"/>
                    <measurement group_id="O4" value="6.0"/>
                    <measurement group_id="O5" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Injection Site Adverse Events</title>
        <description>Injection site adverse events included injection site bruising, discomfort, erythema, hemorrhage, induration, inflammation, pain, paresthesia, pruritus, swelling, urticaria, reaction and rash.</description>
        <time_frame>Baseline up to Day 211 for 28 days groups and Baseline up to Day 225 for 14 days groups</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Injection Site Adverse Events</title>
          <description>Injection site adverse events included injection site bruising, discomfort, erythema, hemorrhage, induration, inflammation, pain, paresthesia, pruritus, swelling, urticaria, reaction and rash.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of PF-04950615 at Week 12 and 24</title>
        <time_frame>Week 12, 24</time_frame>
        <population>Analysis set included all participants who received at least 1 dose of PF-04950615. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of PF-04950615 at Week 12 and 24</title>
          <population>Analysis set included all participants who received at least 1 dose of PF-04950615. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>Microgram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0157" spread="2.09363"/>
                    <measurement group_id="O2" value="1.4737" spread="1.35406"/>
                    <measurement group_id="O3" value="2.0516" spread="2.25916"/>
                    <measurement group_id="O4" value="0.5035" spread="0.53400"/>
                    <measurement group_id="O5" value="2.2010" spread="3.91444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7951" spread="0.78411"/>
                    <measurement group_id="O2" value="1.1605" spread="0.72802"/>
                    <measurement group_id="O3" value="1.6500" spread="2.77210"/>
                    <measurement group_id="O4" value="0.3752" spread="0.41778"/>
                    <measurement group_id="O5" value="1.6459" spread="4.20348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Low Density Lipoprotein-cholesterol Less Than (&lt;) 100, &lt;70, &lt;40 and &lt;25 Milligram Per Deciliter (mg/dL)</title>
        <time_frame>Week 12, 24</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Every 14 Days</title>
            <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04950615 50 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04950615 100 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04950615 150 mg: Every 14 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Every 28 Days</title>
            <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>PF-04950615 200 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>PF-04950615 300 mg: Every 28 Days</title>
            <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Low Density Lipoprotein-cholesterol Less Than (&lt;) 100, &lt;70, &lt;40 and &lt;25 Milligram Per Deciliter (mg/dL)</title>
          <population>FAS included all participants who were randomized. Here, &quot;Number Analyzed&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12: &lt;100 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="90.9"/>
                    <measurement group_id="O3" value="95.2"/>
                    <measurement group_id="O4" value="91.3"/>
                    <measurement group_id="O5" value="34.8"/>
                    <measurement group_id="O6" value="64.6"/>
                    <measurement group_id="O7" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &lt;100 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6"/>
                    <measurement group_id="O2" value="86.0"/>
                    <measurement group_id="O3" value="91.1"/>
                    <measurement group_id="O4" value="91.5"/>
                    <measurement group_id="O5" value="44.2"/>
                    <measurement group_id="O6" value="78.7"/>
                    <measurement group_id="O7" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: &lt;70 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="78.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &lt;70 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="73.3"/>
                    <measurement group_id="O4" value="68.1"/>
                    <measurement group_id="O5" value="2.3"/>
                    <measurement group_id="O6" value="21.3"/>
                    <measurement group_id="O7" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: &lt;40 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="47.8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &lt;40 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="17.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2.1"/>
                    <measurement group_id="O7" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: &lt;25 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="48"/>
                    <count group_id="O7" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="10.9"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="2.1"/>
                    <measurement group_id="O7" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &lt;25 mg/dL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                    <count group_id="O7" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>14.964</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.997</ci_lower_limit>
            <ci_upper_limit>56.020</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>49.615</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.984</ci_lower_limit>
            <ci_upper_limit>308.328</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>12.842</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.674</ci_lower_limit>
            <ci_upper_limit>44.892</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.107</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.304</ci_lower_limit>
            <ci_upper_limit>7.401</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.402</ci_lower_limit>
            <ci_upper_limit>15.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>12.773</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.932</ci_lower_limit>
            <ci_upper_limit>41.495</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>36.886</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.330</ci_lower_limit>
            <ci_upper_limit>163.335</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>20.750</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.741</ci_lower_limit>
            <ci_upper_limit>75.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.219</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.061</ci_lower_limit>
            <ci_upper_limit>18.764</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 100 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.205</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.060</ci_lower_limit>
            <ci_upper_limit>18.693</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 70 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>27.703</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.752</ci_lower_limit>
            <ci_upper_limit>133.423</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 70 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>71.177</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.783</ci_lower_limit>
            <ci_upper_limit>367.564</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 70 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>100.667</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.855</ci_lower_limit>
            <ci_upper_limit>510.387</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 70 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 70 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>24.941</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.336</ci_lower_limit>
            <ci_upper_limit>98.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 70 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>80.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.094</ci_lower_limit>
            <ci_upper_limit>353.742</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 70 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>42.101</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.621</ci_lower_limit>
            <ci_upper_limit>166.894</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 70 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.700</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.396</ci_lower_limit>
            <ci_upper_limit>98.075</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 70 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>36.841</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.527</ci_lower_limit>
            <ci_upper_limit>299.817</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 40 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 40 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 40 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 40 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 40 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 40 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 25 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 25 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 12, Less than 25 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 25 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.587</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 25 mg/dL.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24, Less than 25 mg/dL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.925</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an adverse event (AE) and a serious AE. However, what are presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study. Safety analysis set included all participants who received at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo: Every 14 Days</title>
          <description>Participants received single dose of subcutaneous (SC) injection of placebo matched to PF-04950615 once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>PF-04950615 50 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 50 milligram (mg) once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>PF-04950615 100 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 100 mg once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="E4">
          <title>PF-04950615 150 mg: Every 14 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 150 mg once every 14 days for 24 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo: Every 28 Days</title>
          <description>Participants received single dose of SC injection of placebo matched to PF-04950615 once every 28 days for 24 weeks.</description>
        </group>
        <group group_id="E6">
          <title>PF-04950615 200 mg: Every 28 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 200 mg once every 28 days for 24 weeks.</description>
        </group>
        <group group_id="E7">
          <title>PF-04950615 300 mg: Every 28 Days</title>
          <description>Participants received single dose of SC injection of PF-04950615 300 mg once every 28 days for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Exposure via father</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer stage II</sub_title>
                <description>This event was gender specific.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic dysplasia</sub_title>
                <description>This event was gender specific.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations or caveats in this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

